547 related articles for article (PubMed ID: 20623530)
1. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals.
Lu J; Liong M; Li Z; Zink JI; Tamanoi F
Small; 2010 Aug; 6(16):1794-805. PubMed ID: 20623530
[TBL] [Abstract][Full Text] [Related]
2. PEG-templated mesoporous silica nanoparticles exclusively target cancer cells.
Morelli C; Maris P; Sisci D; Perrotta E; Brunelli E; Perrotta I; Panno ML; Tagarelli A; Versace C; Casula MF; Testa F; Andò S; Nagy JB; Pasqua L
Nanoscale; 2011 Aug; 3(8):3198-207. PubMed ID: 21725561
[TBL] [Abstract][Full Text] [Related]
3. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
4. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles.
Yan Y; Fu J; Wang T; Lu X
Acta Biomater; 2017 Mar; 51():471-478. PubMed ID: 28131940
[TBL] [Abstract][Full Text] [Related]
5. Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis.
She X; Chen L; Yi Z; Li C; He C; Feng C; Wang T; Shigdar S; Duan W; Kong L
Mini Rev Med Chem; 2018; 18(11):976-989. PubMed ID: 27145854
[TBL] [Abstract][Full Text] [Related]
6. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
[TBL] [Abstract][Full Text] [Related]
7. Mesoporous silica nanoparticles for therapeutic/diagnostic applications.
Jafari S; Derakhshankhah H; Alaei L; Fattahi A; Varnamkhasti BS; Saboury AA
Biomed Pharmacother; 2019 Jan; 109():1100-1111. PubMed ID: 30551360
[TBL] [Abstract][Full Text] [Related]
8. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
[TBL] [Abstract][Full Text] [Related]
9. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
Zhang W; Liu M; Liu A; Zhai G
Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
[TBL] [Abstract][Full Text] [Related]
10. Functionalized Mesoporous Silica Nanoparticles for Drug-Delivery to Multidrug-Resistant Cancer Cells.
Igaz N; Bélteky P; Kovács D; Papp C; Rónavári A; Szabó D; Gácser A; Kónya Z; Kiricsi M
Int J Nanomedicine; 2022; 17():3079-3096. PubMed ID: 35859731
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution.
Baeza A; Manzano M; Colilla M; Vallet-Regí M
Biomater Sci; 2016 May; 4(5):803-13. PubMed ID: 26902682
[TBL] [Abstract][Full Text] [Related]
12. Mesoporous silica nanoparticles: synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery.
Li Z; Zhang Y; Feng N
Expert Opin Drug Deliv; 2019 Mar; 16(3):219-237. PubMed ID: 30686075
[TBL] [Abstract][Full Text] [Related]
13. Targeted Mesoporous Silica Nanocarriers in Oncology.
Baeza A; Vallet-Regi M
Curr Drug Targets; 2018 Feb; 19(3):213-224. PubMed ID: 27262488
[TBL] [Abstract][Full Text] [Related]
14. Biomedical application of mesoporous silica nanoparticles as delivery systems: a biological safety perspective.
Hosseinpour S; Walsh LJ; Xu C
J Mater Chem B; 2020 Nov; 8(43):9863-9876. PubMed ID: 33047764
[TBL] [Abstract][Full Text] [Related]
15. Mesoporous silica nanoparticles in medicine--recent advances.
Mamaeva V; Sahlgren C; Lindén M
Adv Drug Deliv Rev; 2013 May; 65(5):689-702. PubMed ID: 22921598
[TBL] [Abstract][Full Text] [Related]
16. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery.
Tang F; Li L; Chen D
Adv Mater; 2012 Mar; 24(12):1504-34. PubMed ID: 22378538
[TBL] [Abstract][Full Text] [Related]
17. Injectable hydrogel imbibed with camptothecin-loaded mesoporous silica nanoparticles as an implantable sustained delivery depot for cancer therapy.
Min Jung J; Lip Jung Y; Han Kim S; Sung Lee D; Thambi T
J Colloid Interface Sci; 2023 Apr; 636():328-340. PubMed ID: 36638572
[TBL] [Abstract][Full Text] [Related]
18. Mesoporous Silica Nanoparticles in Cancer Therapy: Relevance of the Targeting Function.
Pasqua L; Leggio A; Sisci D; Andò S; Morelli C
Mini Rev Med Chem; 2016; 16(9):743-53. PubMed ID: 26996622
[TBL] [Abstract][Full Text] [Related]
19. A systemic review on development of mesoporous nanoparticles as a vehicle for transdermal drug delivery.
Kolimi P; Narala S; Youssef AAA; Nyavanandi D; Dudhipala N
Nanotheranostics; 2023; 7(1):70-89. PubMed ID: 36593800
[TBL] [Abstract][Full Text] [Related]
20. Lactosaminated mesoporous silica nanoparticles for asialoglycoprotein receptor targeted anticancer drug delivery.
Quan G; Pan X; Wang Z; Wu Q; Li G; Dian L; Chen B; Wu C
J Nanobiotechnology; 2015 Feb; 13():7. PubMed ID: 25643602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
